Any current/future new fundraising through debt or equity?

Deferred payments from the Viatris acquisition are due in FY '25; these will be paid through a combination of internal accruals and other planned fund flows (Page 15). No specific mention of new fundraising through debt or equity during the call. Current debt of US$1.2 billion is structured with one-third hedged, one-third open for early prepayment, and one-third exposed to interest rate movements; no new debt issuance announced (Page 10). The company is focused on paying down existing debts as cash flows improve (Page 17). No announcements or indications of plans for fresh fundraising thr

Any current/future capex/capital investment/strategic investment?

Completed process validation of greenfield immunosuppressant API facility in Visakhapatnam, with commercial supplies expected to begin in FY'25 post regulatory qualification. Acquired a U.S. FDA-approved oral solid dosage manufacturing facility of Eywa Pharma in New Jersey to enhance manufacturing capacity and diversify infrastructure for new products and supply continuity. Ongoing focus on increased investments in portfolio, R&D capabilities, and infrastructure to deliver on strategic plans. Bicara, a Biocon subsidiary, is progressing with a US$108 million Series B financing, advancing

Future growth expectations in sales/revenue/volumes?

Biocon Biologics aims to deliver US$1 billion revenue in FY24, with ongoing growth driven by commercial products and market share gains in the U.S. and Europe. Future growth catalysts include biosimilars like Adalimumab, Aspart, Bevacizumab, Aflibercept, Ustekinumab, and Denosumab targeting a combined market opportunity of US$25 billion. New product launches are planned almost every year through 2030, supporting sustained revenue growth. The company expects growth from increasing depth in emerging markets supported by strong insulin demand and new launches. Expansion is supported by transition

Future growth expectations in earnings/operating earnings/profits/EPS?

Biocon Biologics aims to deliver US$1 billion revenue for full year FY24, with growth driven by biosimilar product launches and commercial traction in major geographies (US, EU, emerging markets). Profit before tax (PBT) is currently negative ₹15 crores but expected to improve with revenue growth and scale benefits. Core EBITDA margins remain healthy, around mid-30s percentage, reflecting operational leverage despite increased R&D and amortization costs. Ongoing R&D investments (~10-11% of revenues) focus on biosimilars and peptides (GLP-1s), anticipated to drive future revenue streams a

BioconQ2 FY24Pharmaceuticals & Biotechnology

Biocon Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹371P/E: 85.6Market Cap: ₹62.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Biocon Biologics aims to deliver US$1 billion revenue in FY24, with ongoing growth driven by commercial products and market share gains in the U.S. and Europe.
Future growth catalysts include biosimilars like Adalimumab, Aspart, Bevacizumab, Aflibercept, Ustekinumab, and Denosumab targeting a combined market opportunity of US$25 billion.
New product launches are planned almost every year through 2030, supporting sustained revenue growth.
The company expects growth from increasing depth in emerging markets supported by strong insulin demand and new launches.
Expansion is supported by transitioning to a fully integrated biosimilars enterprise and vertical integration enhancing competitiveness.
Growth is also expected from peptides and GLP-1 related opportunities in the Generics business.
Market share gains in insulin and oncology biosimilars in the U.S., Europe, and other markets continue with steady volume growth offsetting price erosion.

Margin guidance

Category 3

Biocon Biologics aims to deliver US$1 billion revenue for full year FY24, with growth driven by biosimilar product launches and commercial traction in major geographies (US, EU, emerging markets).
Profit before tax (PBT) is currently negative ₹15 crores but expected to improve with revenue growth and scale benefits.
Core EBITDA margins remain healthy, around mid-30s percentage, reflecting operational leverage despite increased R&D and amortization costs.
Ongoing R&D investments (~10-11% of revenues) focus on biosimilars and peptides (GLP-1s), anticipated to drive future revenue streams and margins over the medium to long term.
New product approvals and launches, including biosimilars like Aflibercept, Ustekinumab, and Denosumab, represent a US$25 billion sales opportunity, supporting sustained earnings growth.
Generics and Research Services businesses are also showing steady revenue and EBITDA growth, contributing to overall profitability improvement.
Margin expansion expected as licensing income normalizes and commercial portfolio execution strengthens.

See what Biocon management said on margin guidance — free account, 30 seconds.

Fundraise plans

Deferred payments from the Viatris acquisition are due in FY '25; these will be paid through a combination of internal accruals and other planned fund flows (Page 15).
No specific mention of new fundraising through debt or equity during the call.
Current debt of US$1.2 billion is structured with one-third hedged, one-third open for early prepayment, and one-third exposed to interest rate movements; no new debt issuance announced (Page 10).
The company is focused on paying down existing debts as cash flows improve (Page 17).
No announcements or indications of plans for fresh fundraising through equity were made in the call.

Order book

The transcript provided does not explicitly mention Biocon Limited's current or expected order book or pending orders. However, from the information given, some relevant insights can be summarized as: - Biocon Biologics is on track for a US$1 billion revenue target for FY24, indicating a strong order flow and sales momentum. - The transition and integration of acquired businesses continue, supporting future growth with new product launches planned almost every year through 2030. - Several biosimilars and generic formulations have received regulatory approvals, supporting order inflows. - The company is engaged with payors in the U.S. and Europe to expand market access, which implies active commercial orders. - Manufacturing partnerships such as with Zoetis for biologics are progressing, likely contributing to the order pipeline. - Regulatory inspections and capacity expansions (e.g., immunosuppressant API facility) suggest preparation for future demand. No direct quantification of order book or pending orders is disclosed in the transcript.

See what Biocon management said on order book — free account, 30 seconds.

Capex plans

Yes

Completed process validation of greenfield immunosuppressant API facility in Visakhapatnam, with commercial supplies expected to begin in FY'25 post regulatory qualification.
Acquired a U.S. FDA-approved oral solid dosage manufacturing facility of Eywa Pharma in New Jersey to enhance manufacturing capacity and diversify infrastructure for new products and supply continuity.
Ongoing focus on increased investments in portfolio, R&D capabilities, and infrastructure to deliver on strategic plans.
Bicara, a Biocon subsidiary, is progressing with a US$108 million Series B financing, advancing pipeline development including BCA101.
No specific new large-scale capex announced but strategic investments aligned with growing global biosimilars demand and expanding commercial footprint in the U.S., Europe, and other markets.

Track Biocon — get its next earnings analysis in your feed

How does Biocon rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBiocon

Rev 2Mar 3

See where Biocon sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Biocon rank in Pharmaceuticals & Biotechnology?

Compare Biocon against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Biocon's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →